Histopathology and antifungal treatment of experimental murine chromoblastomycosis caused by Cladophialophora carrionii

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 666-670

  Calvo, Enrique ^a   Pastor, F Javier ^a   Salas, Valentina ^a   Mayayo, Emilio ^a   Capilla, Javier ^a   Guarro, Josep ^a  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

C. carrionii; Cutaneous infections; Mice

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CHROMOMYCOSIS; CLADOPHIALOPHORA CARRIONII; CLADOSPORIUM; CONTROLLED STUDY; DRUG EFFICACY; FUNGUS GROWTH; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; TREATMENT DURATION;

ANIMALS; ANTIFUNGAL AGENTS; ASCOMYCOTA; CHROMOBLASTOMYCOSIS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, NUDE; TREATMENT OUTCOME;

EID: 84856971029     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr537     Document Type: Article

References (37)

1. Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol 2009; 34: 849-54.
2. López Martínez R, Méndez Tovar LJ. Chromoblastomycosis. Clin Dermatol 2007; 25: 188-94.
3. Queiroz-Telles F, Esterre P, Pérez-Blanco M et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2009; 47: 3-15.
4. Bonifaz A, Paredes-Solís V, Saú l A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother 2004; 5: 247-54.
5. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis 2006; 19: 148-52.
6. Queiroz-Telles F, Nucci M, Colombo AL et al. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol 2011; 49: 225-36.
7. Ahrens J, Graybill JR, Abishawl A et al. Experimental murine chromomycosis mimicking chronic progressive human disease. Am J Trop Med Hyg 1989; 40: 651-8.
8. Calvo E, Pastor FJ, Mayayo E et al. Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi. Antimicrob Agents Chemother 2011; 55: 3709-13.
9. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
10. Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000; 38: 209-12.
11. Warn PA, Sharp A, Mosquera J et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus avus. J Antimicrob Chemother 2006; 58: 1198-207.
12. Gonzá lez GM, Fothergill AW, Sutton DA et al. In vitro activities of new and established triazoles against opportunistic lamentous and dimorphic fungi. Med Mycol 2005; 43: 281-4.
13. Vitale RG, Perez-Blanco M, De Hoog GS. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med Mycol 2009; 47: 35-40.
14. Sugar AM, Liu XP. Efcacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001; 45: 601-4.
15. MacCallum DM, Odds FC. Inuence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J Antimicrob Chemother 2002; 50: 219-24.
16. Kan VL, Bennett JE. Efcacies of four antifungal agents in experimental sporotrichosis. Antimicrob Agents Chemother 1988; 32: 1619-23.
17. Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-42.
18. Krishna G, Beresford E, Ma L et al. Skin concentrations and pharmacokinetics of posaconazole after oral administration. Antimicrob Agents Chemother 2010; 54: 1807-10.
19. Trilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-13.
20. Leyden J. Pharmacokinetics and pharmacology of terbinane and itraconazole. J Am Acad Dermatol 1998; 38: S42-7.
21. Defaveri J, Graybill JR. Treatment of chronic murine chromoblastomycosis with the triazole SCH39304. Am J Trop Med Hyg 1990; 42: 601-6.
22. Gupta AK, Taborka PR, Sanzovo AD. Alternate week and combination itraconazole and terbinane therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 2002; 40: 529-34.
23. Andrade TS, Castro LG, Nunes RS et al. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 2004; 47: 216-21.
24. Fung SL, Chau CH, Yew WW. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J 2008; 32: 240.
25. Bonifaz A, Saúl A, Paredes-Solis V et al. Treatment of chromoblastomycosis with terbinane: experience with four cases. J Dermatolog Treat 2005; 16: 47-51.
26. Ajit C, Suvannasankha A, Zaeri N et al. Terbinane-associated hepatotoxicity. Am J Med Sci 2003; 325: 292-5.
27. Guarro J. Lessons from animals studies for the treatment of invasive human infections due to uncommon fungi. J Antimicrob Chemother 2011; 66: 1447-66.
28. Dupont C, Duong TA, Mallet S et al. Unusual presentation of chromoblastomycosis due to Cladophialophora carrionii in a renal and pancreas transplant recipient successfully treated with posaconazole and surgical excision. Transpl Infect Dis 2010; 12: 180-3.
29. Negroni R, Tobón A, Bustamante B et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Trop Sao Paulo 2005; 47: 339-46.
30. Criado PR, Careta MF, Valente NY et al. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy. J Dermatolog 2011; 22: 167-74.
31. Raad II, Graybill JR, Bustamante AB et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 15: 1726-34.
32. Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev 2010; 23: 884-928.
33. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
34. Fica A, Diaz MC, Luppi M et al. Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana. Scand J Infect Dis 2003; 35: 892-3.
35. Lyons MK, Blair JE, Leslie KO. Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana. Clin Neurol Neurosurg 2005; 107: 532-4.
36. Koo S, Klompas M, Marty FM. Fonsecaea monophora cerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review. Med Mycol 2010; 48: 769-74.
37. Hamza SH, Mercado PJ, Skelton HG et al. An unusual dematiaceous fungal infection of the skin caused by Fonsecaea pedrosoi: a case report and review of the literature. J Cutan Pathol 2003; 30: 340-3.